Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 5/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.39 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | GAPDH | P04406 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22034200 | 0.91 | TYMP (0.48) | TYMPPRMT6P2RY12ADORA1GAPDH | |
| SCHEMBL21750459 | 0.91 | TYMP (0.48) | TYMPPRMT6P2RY12ADORA1GAPDH | |
| SCHEMBL22033791 | 0.89 | TYMP (0.55) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL22034224 | 0.89 | TYMP (0.55) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL22034198 | 0.87 | TYMP (0.50) | TYMPPRMT6P2RY12ADORA1ADORA2A | |
| SCHEMBL18496425 | 0.86 | TYMP (0.45) | TYMPPRMT6P2RY12ADORA1GAPDH | |
| SCHEMBL8380846 | 0.84 | TYMP (0.51) | TYMPPRMT6P2RY12ADORA1ADORA2A | |
| SCHEMBL22034202 | 0.84 | TYMP (0.49) | TYMPPRMT6P2RY12ADORA1ADORA2A | |
| SCHEMBL18917304 | 0.84 | TYMP (0.49) | TYMPPRMT6P2RY12ADORA1ADORA2A | |
| SCHEMBL6404792 | 0.83 | TYMP (0.53) | TYMPPRMT6PRKAG1PRKAA1PRKAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024964-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-01-27 | — | — | US | disclosed |
| EP-3891164-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | Merck Sharp & Dohme Corp. (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020117625-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024964-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | TYMP 2010/4885PRMT6 3982/4885PRKAG1 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.